Molly Henderson - 06 Apr 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Signature
/s/ Larry Miller, Attorney-in-Fact for Molly Henderson
Issuer symbol
PHAT
Transactions as of
06 Apr 2023
Net transactions value
-$25,002
Form type
4
Filing time
07 Apr 2023, 15:18:03 UTC
Previous filing
03 Mar 2023
Next filing
23 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Sale $25,002 -3,439 -4.5% $7.27 72,576 06 Apr 2023 Direct F1, F2
holding PHAT Common Stock 339 06 Apr 2023 by 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022.
F2 Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.